Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline

3 weeks ago 10

Sheryar Siddiq

Sat, November 29, 2025 astatine 12:09 PM CST 1 min read

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best dilatory maturation stocks to put in. On November 21, Mizuho accrued its terms people for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 portion maintaining the stock’s Outperform rating. The steadfast cited a fig of factors for the adjustment, including a longer exclusivity play for Biktarvy, with a US nonaccomplishment of exclusivity present anticipated successful 2036 alternatively than the erstwhile estimation of 2033 owed to generic litigation settlements.

Yeztugo’s marketplace imaginable was besides emphasized by the company, which stated that the pre-exposure prophylaxis marketplace mightiness beryllium “much larger than presently appreciated,” perchance reaching $15–20 billion.

Even so, Gilead Sciences, Inc. (NASDAQ:GILD) has been nether unit for definite different products. A Phase 3 proceedings for HR+/HER2-negative metastatic bosom crab revealed that Gilead Science’s crab medicine Trodelvy failed to fulfill its superior objective. The ASCENT-07 trial, which compared Trodelvy against chemotherapy, was incapable to conscionable its main nonsubjective of progression-free survival.

Gilead Sciences Inc. (NASDAQ:GILD) is simply a biopharmaceutical institution that discovers, develops, and commercializes medicines successful the areas of unmet aesculapian request successful the US, Europe, and internationally.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.